<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933292</url>
  </required_header>
  <id_info>
    <org_study_id>OS-2</org_study_id>
    <nct_id>NCT04933292</nct_id>
  </id_info>
  <brief_title>A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome</brief_title>
  <official_title>A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaoli Fan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current standard therapy of primary biliary cholangitis-autoimmune hepatitis overlap&#xD;
      syndrome(PBC-AIH overlap) consists of a combination of prednisolone and azathioprine.&#xD;
      However, a significant proportion of patients may do not respond to, or is intolerant for&#xD;
      azathioprine. Several studies have documented the efficacy and safety of mycophenolate&#xD;
      mofetil(MMF) as second-line therapy for PBC-AIH overlap. However, robust evidence from a&#xD;
      formal randomized clinical trial for the first-line immunosuppressor is in need.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of patients in remission, defined as normalization of serum transaminase and IgG levels after 6 months of treatment, per treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of IgG value in both groups</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of IgG value in both groups</measure>
    <time_frame>at 3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of IgG value in both groups</measure>
    <time_frame>at 6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone and Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone and Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone and Mycophenolate mofetil</intervention_name>
    <description>Methylprednisolone combination of mycophenolate mofetil</description>
    <arm_group_label>Methylprednisolone and Mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone and azathioprine</intervention_name>
    <description>Methylprednisolone combination of azathioprine</description>
    <arm_group_label>Methylprednisolone and Azathioprine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-70 years;&#xD;
&#xD;
          2. Diagnosed with PBC-AIH overlap syndrome according to Paris criteria;&#xD;
&#xD;
          3. Agreed to participate in the trial, and assigned informed consent;&#xD;
&#xD;
          4. The WBC count ≥2.5x10^9/L and platelet count ≥50x10^9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of hepatitis A, B, C, D, or E virus infection;&#xD;
&#xD;
          2. Patients with presence of serious decompensated cirrhosis;&#xD;
&#xD;
          3. Patients have a history of glucocorticoid or immunosuppressant medication before&#xD;
             enrollment;&#xD;
&#xD;
          4. Liver damage caused by other reasons: such as primary sclerosing cholangitis,&#xD;
             non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease.&#xD;
&#xD;
          5. Pregnant and breeding women;&#xD;
&#xD;
          6. Severe disorders of other vital organs, such as severe heart failure, cancer;&#xD;
&#xD;
          7. Parenteral administration of blood or blood products within 6 months before screening;&#xD;
&#xD;
          8. Recent treatment with drugs having known liver toxicity;&#xD;
&#xD;
          9. Taken part in other clinic trials within 6 months before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoli Fan, Master degree</last_name>
    <phone>+86 13980433451</phone>
    <email>13980433451@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan Univerisity</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Fan, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoli Fan</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

